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Williams-Beuren syndrome (WBS), caused by a heterozygous deletion at 7q11.23, represents a model for studying
hypertension, the leading risk factor for mortality worldwide, in a genetically determined disorder. Haploinsufﬁ-
ciency at the elastin gene is known to lead to the vascular stenoses in WBS and is also thought to predispose to
hypertension, present in ∼50% of patients. Detailed clinical and molecular characterization of 96 patients with
WBS was performed to explore clinical-molecular correlations. Deletion breakpoints were precisely deﬁned and
were found to result in variability at two genes, NCF1 and GTF2IRD2. Hypertension was signiﬁcantly less prevalent
in patients with WBS who had the deletion that included NCF1 ( ), a gene coding for the p47phox subunitPp .02
of the NADPH oxidase. Decreased p47phox protein levels, decreased superoxide anion production, and lower protein
nitrotyrosination were all observed in cell lines from patients hemizygous at NCF1. Our results indicate that the
loss of a functional copy of NCF1 protects a proportion of patients with WBS against hypertension, likely through
a lifelong reduced angiotensin II–mediated oxidative stress. Therefore, antioxidant therapy that reduces NADPH
oxidase activity might have a potential beneﬁt in identiﬁable patients with WBS in whom serious complications
related to hypertension have been reported, as well as in forms of essential hypertension mediated by a similar
pathogenic mechanism.
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Williams-Beuren syndrome (WBS [MIM 194050]) is a
neurodevelopmental disorder with multisystemic mani-
festations and a prevalence in newborns that ranges be-
tween 1/7,500 and 1/20,000 (Greenberg 1990; Stromme
et al. 2002). The WBS phenotype includes distinctive fa-
cial features; vascular stenoses, most notably supravalvar
aortic stenosis (SVAS); global cognitive deﬁcit, with an
asymmetric neurobehavioral proﬁle; and transient hyper-
calcemia of infancy. WBS is caused by a segmental aneu-
somy of 1.55–1.83 Mb at chromosomal band 7q11.23,
which includes ELN (coding for elastin [MIM 130160])
and 25–27 additional genes (Francke 1999; Peoples et
al. 2000; Pe´rez Jurado 2003). The WBS deletion is me-
diated by nonallelic homologous recombination (NAHR)
between regional segmental duplications or low-copy
repeats (LCRs) that ﬂank the region. Each of the LCR
blocks that mediate most deletions, called “blocks B,”
contain three transcription units, which are either func-
tional genes or pseudogenes, depending on their loca-
tion (Valero et al. 2000). GTF2I (general transcription
factor II-I [MIM 601679]) and NCF1 (neutrophilic cy-
tosolic factor 1 [MIM 608512]) have been shown to be
functional only from a single locus located in the me-
dial block B (Bm) (Gorlach et al. 1997; Pe´rez Jurado et
al. 1998), whereas the other two copies located in the
centromeric (Bc) and telomeric (Bt) blocks are pseudo-
genes with truncating mutations. The third transcription
unit, GTF2IRD2 (alpha [MIM 608899] and beta [MIM
608900]), which codes for a protein of unknown func-
tion but related to GTF2I, appears to be functional in
two of the three copies: those located in Bm and Bt
(Tipney et al. 2004; Antonell et al. 2005). Despite the
fact that the great majority of patients have deletions
very similar in size, the WBS phenotype is highly vari-
able, and the molecular bases of this variability are still
unknown. Hemizygosity at ELN is known to be the
cause of the vascular stenoses that lead to clinically rec-
ognized cardiovascular involvement in as many as 75%
of patients and is also thought to predispose to hyper-
tension. Additional candidates for involvement in several
aspects of the WBS phenotype have been proposed on
the basis of clinical-molecular correlations in patients
with partial phenotypes and smaller deletions (Hirota et
al. 2003; Morris et al. 2003; Pe´rez Jurado 2003; Tassa-
behji 2003; Howald et al. 2005; Tassabehji et al. 2005).
However, deﬁnitive pathogenetic implication of the genes
in the deletion or ﬂanking regions, other than ELN, is
still uncertain.
Hypertension is the leading risk factor for mortality
worldwide, affecting 26% of the adult population over-
all, and these numbers are predicted to increase by∼60%
in the next 20 years (Kearney et al. 2005). Understanding
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the pathogenic mechanisms involved in this condition is
one of the highest priorities for public health, to better
diagnose, treat, and prevent the disorder. There are mul-
tiple genetic and environmental factors contributing to
human hypertension, and a role for oxidative stress seems
to be somehow present in most forms (Touyz 2005).
WBS represents a model for studying the pathogenic
mechanism of hypertension in a genetically determined
disorder. Interestingly, the hypertension found in ∼50%
of young adults with WBS is not often associated with
visible vascular stenoses of their descending aortas or
renal arteries on abdominal Doppler ultrasound, a fact
that speaks against vascular narrowing alone as the de-
terminant factor for hypertension (Cherniske et al. 2004).
Thus, high blood pressure in WBS appears to fall in the
category of essential hypertension with no well-deﬁned
structural cause, since anatomic renovascular hyperten-
sion is a very infrequent ﬁnding.
We have characterized the clinical features of 96 pa-
tients with WBS and have performed ﬁne mapping of the
deletions, to investigate whether variation in the break-
point may affect different genes implicated in this vari-
able phenotype. We have determined that the occurrence
of hypertension in WBS is not correlated at all with the
severity of the cardiovascular lesions. Instead, hyperten-
sion occurs with signiﬁcantly lower frequency in patients
whose deletion includes a functional copy of the gene
NCF1,which encodes the p47phox subunit of theNADPH
oxidase (NOX) complex. Therefore, for patients with
WBS, hemizygosity forNCF1 is a protective factor against
hypertension. This ﬁnding implicates oxidative stress di-
rectly in the pathogenesis of hypertension in WBS and
suggests that there is a potential role for antioxidant
pharmacological intervention to prevent its development
in WBS, as well as other forms of hypertension mediated
by a similar mechanism.
Material and Methods
Subjects
Major clinical characteristics were analyzed in 96 patients
with the phenotype of sporadic WBS and a conﬁrmed deletion
at 7q11.23 who were referred from multiple clinical centers
in Spain. Patients’ anthropometrical measurements were com-
pared with normal andWBS standards (Hall et al. 1989; Partsch
et al. 1999). All patients were evaluated using a similar proto-
col for data collection and physical exam. Blood pressure was
taken during morning hours, to avoid any factor that could
increase anxiety, and on at least two separate occasions. For
this study, hypertension was deﬁned as blood pressure mea-
surements 190th percentile for age and sex (Horan 1987).
Molecular Characterization of the Deletions
PCR analyses of single- andmultiple-copymicrosatelliteswere
performed, to deﬁne the size and parental origin of the dele-
tion; genotyping of paralogous sequence variants, also called
“site-speciﬁc nucleotides” (SSNs), was done thereafter to map
the exact breakpoints of the deletion within block B. PCR con-
ditions and oligonucleotides used for the analyses were as de-
scribed in detail elsewhere (Baye´s et al. 2003).
Signiﬁcance of clinical-molecular correlations was analyzed
using the statistical package SPSS 11.5. Speciﬁcally, the x2 test,
the Fisher’s exact test, the Student’s t test, and logistic regres-
sion were used for the analyses, according to the characteristics
of each variable. Signiﬁcance level was established as .P ! .05
Determination of NCF1 Copy Number
The NCF1 gene can be distinguished from its pseudogenes by
the presence of a 2-bp (GT) deletion at the beginning of exon
2 in the pseudogene copies. PCR reactions were performed
with 50 ng of genomic DNA, PCR buffer, 1.5 mM MgCl2,
1.25 mM of each dNTP, 5 pmol of each primer (one labeled
with HEX ﬂuorochrome), and 0.25 units of Taq polymerase
(Ecogen) on a GeneAmp System 9700 thermocycler (Applied
Biosystems) with the following parameters: a denaturing step
(5 min at 94C), 27 denaturing-annealing-extension cycles (at
94C, 55C, and 72C, for 40 s each), and a ﬁnal extension
(7 min at 72C). Genotyping was performed on an ABI 3100
sequencer, and results were analyzed using the Genescan 3.1
software (Applied Biosystems). Pseudogene/gene ratio quanti-
ﬁcation was performed by comparing the height of the peaks
corresponding to each variant.
Population Study of Essential Hypertension
A population sample composed of individuals randomly se-
lected from cross-sectional studies in the Spanish province of
Girona, to establish the prevalence of cardiovascular factors in
the region (Masia et al. 1998), was also studied for the NCF1
gene:pseudogene variant. Only strictly normotensive adult sub-
jects (diastolic blood pressure !80 mmHg and systolic blood
pressure !135mmHg; ) and deﬁnitely hypertensive sub-np 68
jects (diastolic blood pressure 190 mmHg and systolic blood
pressure 1150 mmHg; ) were considered.np 68
Cell Lines
Epstein-Barr–transformed lymphoblastoid cell lines from in-
dividuals with different NCF1 gene-copy number were grown
in RPMI 1640 medium plus 10% fetal calf serum and anti-
biotics (100 units/ml penicillin and 100 mg/ml streptomycin).
Culture conditions were 37C and 5% CO2. Cells were used
for the experiments while growing in exponential phase. Cell
viability was measured by using the trypan-blue exclusion test,
showing a viability of 98%.
Measurement of NOX Activity
Superoxide anion produced during the respiratory burst by
the NOX activation was evaluated using the reduction of nitro-
blue tetrazolium (NBT) assay (SIGMA), which was performed
as follows. Aliquots of 250 ml of lymphoblastoid cells (10#
/ml) were mixed with 250 ml of NBT (1 mg/ml) in Hank’s610
balanced salt solution (HBSS) (Invitrogen-GIBCO). A dose-re-
sponse curve, with phorbol myristate acetate (PMA) to stimu-
late NOX, determined that 1 mM PMA was suitable to induce
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Table 1
Clinical Features of 96 Patients with WBS
Clinical Feature
No. with Feature/
No. Assessed Percentage
Sex:
Male 51/96 53
Female 45/96 47
Gestational age 141 wks 28/88 32
Birth weight !10th percentile 48/92 52
Height !3rd percentile 51/83 61
Head circumference !10th percentile 27/66 41
WBS facies 96/96 100
WBS personality 96/96 100
Hyperacusis 73/76 96
Cardiovascular lesion 63/96 66
SVAS 42/96 44
PPS 30/96 32
Hypertension: 26/57 46
Systolic 25/57 44
Diastolic 15/57 26
Hypercalcemia 10/63 16
Gastrointestinal symptoms 78/88 89
Urinary tract anomalies 13/60 22
Psychiatric problems 22/60 37
Muscle/skeletal problems 37/63 59
Table 2
Molecular Variants in 96 Patients with WBS
Molecular Variant No. (%) of Subjects
Parental origin of the deletion:
Maternal 48 (50)
Paternal 43 (45)
Unknown 5 (5)
Inversion-mediated deletion:
Yes 24 (25)
No 72 (75)
Deletion size:
1.55 Mb (blocks B) 88 (92)
1.83 Mb (blocks A) 8 (8)
“Functional” copies of NCF1:
1 42 (44)
2 41 (43)
3 12 (12)
4 1 (1)
“Functional” copies of GTF2IRD2:
1M3T 24 (25)
2M2T 53 (55)
1M1Ch2T 11 (12)
1M2T 8 (8)
a positive response. Unstimulated cells were treatedwithHBSS.
After 60 min of incubation at 37C, the reaction was stopped
with 0.5 M HCl, and cells were centrifuged. Supernatants were
discarded, and the reduced NBT was extracted with dioxan.
Supernatant absorbance at 525 nm was determined in an Ul-
trospec 2100-pro spectrophotometer (Amersham Biosciences).
Experiments were performed in duplicate. Data are expressed
as percentages, with the assumption that unstimulated cells
have 100% NOX activity. Data were evaluated statistically by
use of the Student’s t test, with a signiﬁcance level of .P ! .05
Western-Blot Analysis
Cells were lysed and protein concentration was determined
(Bio-Rad). Forty mg of proteins per sample was run in 10%
SDS-PAGE gel for 2 h at 150 V and was transferred onto a
nitrocellulose membrane. Membranes were incubated with a
1:500 mouse antibody (Ab) anti-p47phox (BD Biosciences) and
then with 1:2,000 anti-mouse horseradish peroxidase-linked
Ab (Amersham Biosciences). Loading reference was performed
by use of a 1:5,000 mouse anti–a-tubulin Ab (SIGMA). Pro-
teins were detected by an enhanced chemiluminescence kit
(Pierce). Bands were quantiﬁed with the Scion Image program
(Scion Corporation). The ratio between p47phox and a-tubulin
was calculated to normalize to the amount of protein loaded
per lane.
Immunocytochemistry for p47phox and Detection
of Nitrotyrosination
Approximately lymphoblastoid cells were attached47.5# 10
on 1% poly-L-lysine–coated coverslips by cytospinning. Cells
were ﬁxed and incubated for 2 h at room temperature with
1:300 mouse anti-p47phox monoclonal Ab (BD Biosciences) or
1:400 anti-nitrotyrosine polyclonal Ab (Molecular Probes),
followed by incubation with 1:500 Alexa ﬂuor 488 goat anti-
mouse or anti-rabbit Ab (Molecular Probes) for 1 h at room
temperature. Digital images were taken with a Leica TCS SP
confocal microscope and were analyzed with Leica confocal
software.
Results
Clinical and Molecular Characterization
The clinical features of 96 Spanish patients with classic
WBS, with a mean age of 8.8 years (range 0–28 years),
are shown in table 1. Molecular studies identiﬁed a total
of 88 patients with a 1.55-Mb deletion, mediated by
NAHR between blocks B (ﬁg. 1B), whereas 8 subjects
had a larger (1.83-Mb) deletion, mediated by NAHR
between blocks A (ﬁg. 1A). Of the deletions, 53% oc-
curred in the maternal chromosome, and 47% in the pa-
ternal one. Data at SSNs 8, 10, and 11 permitted infer-
ence that the transmitting progenitor was a carrier of an
inverted chromosome in 25% of cases, as reported else-
where (Baye´s et al. 2003). The analysis of additional
SSNs allowed us to precisely deﬁne the breakpoints be-
tween two SSNs in the recombinant chromosome of each
patient and thus to identify the number of potentially
functional copies of NCF1 and GTF2IRD2 (ﬁg. 1 and
table 2).
At NCF1, we and others have reported a polymor-
phism, likely generated by gene conversion between the
gene and pseudogenes, that results in the presence of
either three (∼15%) or four (∼1%) gene-type copies in
the normal population (Heyworth et al. 2002; Baye´s et
al. 2003). Dependent on the site of the deletion and the
presence or absence of this polymorphism, patients with
536 The American Journal of Human Genetics Volume 78 April 2006 www.ajhg.org
Figure 1 Schematic representation of the common deletions associated with WBS and the characterization of deletion breakpoints. Top,
Scheme of the 7q11.23 genomic region, with the large blocks of segmental duplications represented by black (block C), dark gray (block A),
and light gray (block B) arrows indicating their relative orientation. The three blocks B are differentiated by unblackened (Bc), blackened (Bm),
and diagonally striped (Bt) light gray arrows. The two major types of deletion that cause WBS occur through NAHR mediated by blocks of
segmental duplications that are located in tandem, either blocks Ac and Am (a) or blocks Bc/t and Bm (b). Bottom, Genomic structure and
resulting recombinant block B in patients with the 1.55-Mb deletion. The schematic representation of the entire block with its gene content
(numbered exons of GTF2I, NCF1, and GTF2IRD2) is shown. The location of the multiple SSNs analyzed in this study (with the nucleotide
corresponding to each of the locations Bc, Bm, and Bt) is drawn below (numbered as in the work of Baye´s et al. [2003]). The resulting
chromosomes, depending on deletion breakpoints, are shown with arrows corresponding to functional genes or pseudogenes (marked with an
X) indicating their transcriptional direction. B1, Deletion proximal to the NCF1 gene that does not affect the functional copies of GTF2IRD2.
B2, Deletion causing the loss of NCF1 but not GTF2IRD2. B3, Loss of NCF1 and breakpoint within GTF2IRD2 creating a medial-centromeric
chimeric copy of the gene. B4, Inversion-mediated deletion in which the recombinant chromosome loses NCF1 and a medial copy of GTF2IRD2
but gains a telomeric copy of GTF2IRD2. The numbers of functional copies of NCF1 and GTF2IRD2 corresponding to each rearrangement
are displayed at the right of the ﬁgure. The asterisk (*) indicates that the possibility of additional NCF1 copies due to polymorphism is not
shown in the ﬁgure.
WBS display one, two, three, or four NCF1 gene-type
copies (table 2). Representative results of NCF1 geno-
types in patients with WBS and control individuals are
shown in ﬁgure 2.
At GTF2IRD2, several relevant molecular variants
could also be deﬁned, as shown in ﬁgure 1. Their fre-
quencies are shown in table 2.
Clinical-Molecular Correlations
Since these 96 patients have a conﬁrmed deletion of
the WBS region in band 7q11.23, the frequency of each
of the major clinical features listed in table 1 can be used
to deﬁne theWBS characteristic phenotype and to under-
stand its variability. Some features were age dependent,
such as most skeletal problems (spine curves), which are
present in over half (59%) of patients and appear after
the 1st decade of life ( ; x2 test). Although globalPp .01
cardiovascular involvement was not age dependent, pe-
ripheral pulmonic stenosis (PPS) was signiﬁcantly more
frequent in younger patients, who received diagnoses dur-
ing the 1st decade of life ( ; x2 test). Only cardiacPp .009
involvement was sex dependent; it was clearly more fre-
quent in males ( ; Fisher’s exact test). Except forPp .02
the fact that microcephaly was more frequent in patients
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Figure 2 Representative genotypes at exon 2 of NCF1 of individuals with different pseudogene/gene copy ratios. Each square includes a
genotype with two peaks corresponding to the PCR amplicons of the NCF1 pseudogene (P) and gene (G) copies from several individuals with
WBS with 1.55-Mb (A1–A4) or 1.83-Mb (A5–A7) deletions as well as several controls (B1–B3 and B4, a carrier of autosomal recessive chronic
granulomatous disease). The predicted number of NCF1 pseudogene and gene copies is shown above each peak. The table at the right displays
the actual P/G peak ratio values (mean and range) obtained for each predicted genotype.
with maternal deletions ( ; Fisher’s exact test),Pp .01
no association with parental origin of the deletions was
found with other features. However, there was a non-
signiﬁcant trend for paternal chromosome deletions to
be more frequent in males and for maternal chromo-
some deletions to be more frequent in females (Pp
; Fisher’s exact test)..09
No signiﬁcant associations were found among the dif-
ferent clinical variables. Speciﬁcally, no signiﬁcant asso-
ciations were found between any subtype or degree of
severity of cardiovascular involvement and the presence
of hypertension, neither for systolic nor for diastolic hy-
pertension. Patient ages (mean  SD, years9.7 6.4
with hypertension vs. years without hyper-10.8 7.2
tension), body weights for age, and reported diet and
physical activities were not signiﬁcantly different between
the groups with and without hypertension. None of the
patients with WBS were smokers. Only nine patients
were receiving treatment for established high blood pres-
sure at the time of the evaluation.
With respect to the different molecular variants, hy-
pertension was found with signiﬁcantly different preva-
lence, depending on the number of copies of the func-
tional NCF1 gene. Hypertension was much less frequent
in patients with a single functional copy of NCF1 than
in the rest of the cohort with two or more copies
( ; Fisher’s exact test) (ﬁg. 3). The presence of aPp .02
third or fourth NCF1 copy due to polymorphism was
not signiﬁcantly associated with an increase in the prev-
alence of hypertension, when compared with the most
frequent two-copy variant ( ; Fisher’s exact test).Pp .29
The presence of more than one copy of NCF1 appears
to be associated with an increased risk for hypertension,
with a raw odds ratio of 4.04 (95% CI 1.28–12.84).
Among the four variants of GTF2IRD2 (table 2), the
variant 2M2T, which is associated with no deletion of
NCF1, is thus signiﬁcantly associated with a higher risk
of hypertension ( ; Fisher’s exact test). MultiplePp .01
linear regression analysis to study the impact on hyper-
tension of several variables (sex, age [in decades], paren-
tal origin of the deletion, cardiovascular involvement,
and NCF1 copy number) showed a signiﬁcant adjusted
odds ratio for only NCF1 copy number (odds ratio of
3.62; 95% CI 1.13–11.6).
No other signiﬁcant associations were found among
the remaining clinical and molecular variables.
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Figure 3 Signiﬁcant association between hypertension (1P90p
blood pressure 190th percentile) and NCF1 copy number. The histo-
gram clearly shows that patients with a single copy of NCF1 are over-
represented in the group with normal blood pressure (P90p blood
pressure 90th percentile), whereas patients with two or three NCF1
copies cluster in the hypertension group ( ; Fisher’s exact test).Pp .02
Association Studies of Essential Hypertension
with the NCF1 Copy-Number Polymorphism
To deﬁne whether the NCF1 gene copy-number vari-
ant may have a role in essential hypertension, we geno-
typed 68 adult patients with essential hypertension and
68 age- and sex-matched normotensive controls. The ge-
notype frequencies were not signiﬁcantly different be-
tween both groups. In the group with essential hyperten-
sion, 56 (82.35%) had two NCF1 copies, 11 (16.17%)
had three copies, and 1 (1.47%) had four copies,whereas,
among the normotensive control individuals ( ),np 68
57 (83.82%) showed two copies, 10 (14.7%) showed
three copies, and 1 (1.47%) had four copies ( ;Pp .53
x2 test).
Functional and Expression Studies of Patients
with WBS and Control Individuals with One, Two,
or Three NCF1 Gene-Type Copies
Immunodetection of p47phox in lymphoblastoid cell
lines showed a signiﬁcantly reduced expression of the
protein in cell lines with only one NCF1 gene-type copy,
compared with those with two or three copies (ﬁg. 4A).
This ﬁnding was conﬁrmed by western-blot analysis,
which showed signiﬁcantly lower levels of p47phox pro-
tein ( ; Student’s t test) in cells from patients hemi-Pp .04
zygous for the NCF1 gene (mean result  SE 40.28
arbitrary units [Scion Image software]) than in cells15.3
with two gene-type copies ( ). There was also64.5 4.9
a signiﬁcant increase of protein expression in cell lines
with three copies ( ) ( ; Student’s t test)87.1 8.9 Pp .02
(ﬁg. 4B).
We also tested NBT reduction in cell lines from pa-
tients with WBS who were hemizygous at NCF1 and in
control cell lines with two and three NCF1 gene-type
copies. We observed a signiﬁcant decrease in NBT reduc-
tion for patients with only one gene-type copy of NCF1,
when compared with individuals with two ( ;Pp .007
Student’s t test) or three ( ; Student’s t test)Pp .012
gene-type copies. However, there was no signiﬁcant dif-
ference ( ; Student’s t test) between samples withPp .29
two and three gene-type copies (ﬁg. 4C).
Finally, presuming that a consequence of NCF1 hap-
loinsufﬁciency could be less activity of the NOX com-
plex and higher bioavailability of nitric oxide, we com-
pared basal levels of protein nitrotyrosination between
cell lines by immunocytochemistry. Nitrotyrosination lev-
els were high, on average, although highly variable among
cells with two NCF1 copies, whereas cells with only one
copy showed a more homogeneous pattern, with overall
lower levels of nitrotyrosination (ﬁg. 4D). Protein nitro-
tyrosination reﬂects the effect on proteins of the highly
reactive peroxynitrite, which is formed by the reaction
of superoxide and nitric oxide.
Discussion
We reviewed the major clinical manifestations of 96 pa-
tients with WBS and deﬁned, in detail, their molecular
lesion, including parental origin of the deletions and ﬁne
mapping of the deletion breakpoints. As for other pub-
lished series, the WBS phenotype is complex and vari-
able, and some clinical manifestations are age dependent.
The molecular bases of this phenotypic variability re-
main unknown. Differences in the size or location of the
breakpoints of the deleted interval, genetic variants in
the nondeleted allele, subtle imprinting effects, and the
genetic background and environmental factors may all
contribute to the variable expression of the phenotype.
Partial deletions of the interval have been identiﬁed in
a few atypical patients and have revealed a potential
contribution to the phenotype for the speciﬁc genes for
which the studied families are hemizygous (Hirota et al.
2003; Morris et al. 2003; Pe´rez Jurado 2003; Tassabehji
2003; Howald et al. 2005). However, no cis- or trans-
acting factors have yet been implicated in the etiology
of phenotypic differences in patients with common de-
letions that appear identical in size.
We found interesting associations among the explored
variables, such as cardiovascular stenoses being more fre-
quent in males, as reported elsewhere (Sadler et al. 2001),
and microcephaly occurring more frequently withmater-
nally inherited deletions. Correlation of shorter stature
and microcephaly with maternally inherited deletions
had been suggested in the past but not conﬁrmed in other
series (Pe´rez Jurado et al. 1996; Wang et al. 1999). The
recent ﬁnding of preferential hotspots for NAHR inmale
and female meiosis (L.A.P.J., unpublished data) indicates
that parental origin of the deletion should always be
considered in association with detailed mapping of dele-
tion breakpoints. When that is considered, our results
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Figure 4 Expression and functional analyses of NCF1 copy number in cell lines. A, Immunodetection of p47phox by cytochemistry. B,
Western-blot analysis and quantiﬁcation of expression levels of p47phox versus a-tubulin. Mean values for expression levels in arbitrary units
(AU) for the different groups with 1, 2, and 3 gene-type copies of NCF1 reﬂect an increase in protein expression. An asterisk (*) indicates
signiﬁcant difference ( ). C, Reduction of NBT, shown as the percentage of NOX activation after PMA treatment, with respect to basalP ! .05
conditions for each cell line. Mean values are 155.55, 335.31, and 362.42 for the groups with one, two, and three copies, respectively. The
activation is signiﬁcantly lower when there is one functional copy of the gene, in comparison with two copies ( ; t test) and three copiesPp .006
( ; t test). An asterisk (*) indicates signiﬁcant difference ( ). D, Detection of nitrotyrosination by immunocytochemistry.Pp .01 P ! .05
point again to the possibility that genomic imprinting
that affects genes in the region might play a role in de-
termining head size. This ﬁnding deserves to be explored
in further depth and in larger series as a potential de-
terminant of phenotypic variation.
The most remarkable ﬁnding of this study concerns
hypertension, an important yet inconsistent feature of
WBS. High blood pressure is the only explored clinical
variable strongly associated with the location of the de-
letion breakpoint, such that its prevalence among pa-
tients with WBS is signiﬁcantly increased when NCF1
is not included in the deletion. A signiﬁcant association
is also found for hypertension and some GTF2IRD2
variants. However, although little information is yet avail-
able about GTF2IRD2 function, our data suggest that
it is less likely that GTF2IRD2 is the gene responsible
for the variable blood pressure. Individuals with WBS
who have GTF2IRD2 variants that result in deletion of
one medial copy (1M2T) or a chimeric copy (1M
1Ch2T) are predicted to carry hypomorphic alleles.
The variant 2T2M implies that the WBS chromosome
maintains both functional GTF2IRD2 gene copies, as
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Figure 5 Proposed pathogenic mechanism of hypertension in
WBS. ELN haploinsufﬁciency in all patients with WBS and a 7q11.23
deletion is known to lead to structural changes in vessel walls mediated
by endothelial cell proliferation and smooth-muscle reorganization,
resulting in decreased vascular lumen. The resulting increased wall
stress would lead to chronic activation of the NOX system via angio-
tensin II. Quantitative differences in protein levels of the p47phox sub-
unit, depending on deletion subtypes and the resulting NCF1 copy
number, determine differences in NADPH enzyme bioavailability.There-
fore, patients with a deletion of NCF1 would have a decreased an-
giotensin II–mediated free-radical production and a decreased risk of
hypertension.
in controls, and consequently should be considered nor-
mofunctional, whereas the variant 1M3T could be ei-
ther normofunctional or even hypermorphic, in cases in
which the telomeric and ancestral copy is more active
(Antonell et al. 2005). The two theoretically normo-
functional GTF2IRD2 variants have opposite associa-
tions with hypertension: 2T2M that never entailsNCF1
deletion is strongly associated with hypertension risk,
whereas 1M3T, linked to NCF1 hemizygosity, is asso-
ciated with protection for hypertension. On the contrary,
the predicted hypomorphic variants are not associated
at all with hypertension ( ; Fisher’s exact test).Pp .33
These data suggest that NCF1—and not GTF2IRD2—is
the major player that determines a different prevalence
of hypertension in this population, whereas GTF2IRD2
variants have signiﬁcant association simply becausemost
rearrangements affect NCF1 and GTF2IRD2 together.
NCF1 encodes a cytosolic subunit of NOX complex,
p47phox, which is mutated in the autosomal recessive
form of chronic granulomatous disease (MIM 233700).
We have demonstrated that NCF1 hemizygosity deter-
mines a notable reduction in p47phox protein levels and,
consequently, a signiﬁcant reduction in the ability to gen-
erate oxidative stress through decreased activity of the
NOX complex. This appears to have a protective effect
against hypertension in patients with WBS who are hemi-
zygous for NCF1, who would otherwise be susceptible
to hypertension due to vascular narrowing caused by
ELN deletion. In fact, there is strong evidence that hap-
loinsufﬁciency at the ELN locus predisposes to arterial
vasculopathy, including hypertension. Animal experimen-
tation has shown that decreased elastin leads to struc-
tural changes in vessel walls, with thinner elastic lamellae
and an increased number of smooth-muscle cell layers,
changes also reported in the arteries of patients with
isolated SVAS (Li et al. 1998). These changes in the inner
and outer vessel diameter correlate with alterations in
transmural pressure. Mice with heterozygous Eln dele-
tions are all stably hypertensive and develop mild cardiac
hypertrophy (Faury et al. 2003). These mice have ele-
vated renin levels, and their highermean arterial pressure
can be reduced with angiotensin II inhibitors, which sug-
gests that the renin-angiotensin system plays a signiﬁcant
role in maintaining their high blood pressure.
Compelling evidence has accumulated to support a role
for reactive oxygen species (ROS) in various forms of
hypertension (Touyz 2005). Chronic infusion of angio-
tensin II in rats increases vascular NOX-derived ROS
preceded by a prominent expression of the p47phox sub-
unit of NOX in the vasculature, macula densa, and
distal nephron (Chabrashvili et al. 2002). High intra-
luminal pressure itself, by activating vascular oxidases,
elicits increased superoxide production via activation of
the NOX system (Ungvari et al. 2003). Studies per-
formed inNcf1 knockout mice have revealed that p47phox
is one of the major effectors of angiotensin II action.
The administration of angiotensin II did not lead to in-
creased superoxide production and elevation of blood
pressure in homozygous knockout animals, as it did in
wild-type mice (Landmesser et al. 2002). This knockout
mouse model somehow reproduces the unique situation
in patients with WBS.
We have proven there is dose sensitivity for NCF1 gene
expression and resulting effects on NOX activity. We
therefore propose that the association found between
hypertension and the genotype at NCF1 reﬂects a sig-
niﬁcant implication of redox homeostasis in the patho-
genesis of hypertension in WBS. Elastin deﬁciency leads
to microscopic vascular narrowing and decreased vascu-
lar wall elasticity, regardless of whether it is visible on
standard ultrasound or angiogram imaging. This is a
predisposing factor to angiotensin II elevation, which
may lead to clinical hypertension in only those cases in
which the ability to generate higher oxidative stress is
normal; that is, when two or more active copies ofNCF1
are present (ﬁg. 5). We have also shown that an increase
in NCF1 gene-copy number (three copies), present in
13% of patients, does not lead to increased prevalence
of hypertension in WBS nor does it determine a greater
activation of NOX, despite increased p47phox protein ex-
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pression. In addition, we found identical frequencies of
this genomic variant in a cohort of patients with essential
hypertension and in normotensive controls. Therefore,
this polymorphic variant does not appear to have a sig-
niﬁcant inﬂuence in the etiology of essential hyperten-
sion in the general population. If NCF1 deletion is a
protecting factor for hypertension, why does NCF1 du-
plication not increase the risk? The most likely expla-
nation for this ﬁnding is the fact that the NOX complex
is heteromultimeric and requires stoichiometric amounts
of at least each cytosolic subunit (p40, p47, and p67)
(Lapouge et al. 2002), so that an increase in copy num-
ber of just one of the subunits may not lead to a sig-
niﬁcant increase in the oxidase activity. Alternative ex-
planations are that the extra copies of NCF1 might, in
fact, be nonfunctional pseudogene(s) due to undetected
sequence changes other than the GT insertion/deletion
variant and/or that the polymorphic variant might still
have some inﬂuence, but only when other genetic or
environmental factors concur.
Increasing evidence implicates ROS in the pathogen-
esis of hypertension and its cardiovascular complications
(Touyz 2005). By altering the balance in the endothelium
between vasoconstrictors and vasodilators such as nitric
oxide, ROS contributes to endothelium-dependent con-
tractions and increased vascular resistance. Moreover,
the production of peroxynitrite is damaging to the cells
through nitrotyrosination of proteins. Antioxidants could
restore endothelial function and decrease blood pressure
in several models of hypertension, implicating angioten-
sin II and the redox system (Touyz 2004), but their clin-
ical beneﬁt in essential hypertension in humans remains
unconﬁrmed. In WBS, the results of the present study
suggest that antioxidant treatment could have protective
effects for hypertension, since the pathogenetic implica-
tion of the redox system seems clear. In addition to gen-
eral antioxidants, anti-NADPH agents (still in clinical
trials), the well-known inhibitors of the angiotensin-con-
verting enzyme, and blockers of the angiotensin II re-
ceptor could all have a speciﬁc indication in patientswith
WBS. Given that hypertension causes signiﬁcant mor-
bidity in WBS, contributing to complications such as
stroke, cardiac ischemia, and sudden death (Bird et al.
1996; Wollack et al. 1996), the initiation of clinical trials
in patients with WBS seems pertinent.
Our results also underscore the relevance and poten-
tial success of detailed molecular and clinical character-
ization of patients with a genomic disorder for obtaining
precise correlations that may lead to the determination
of causal genes and pathogenic mechanisms. Future de-
tailed evaluation of other highly variable phenotypic fea-
tures of WBS, such as the complex neurocognitive pro-
ﬁle, is warranted.
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